Company / Return on Equity (ROE)
Lipocine Inc. Return on Equity (ROE) History
FY2013-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
0.0%
FY2025
5-year range
-136.7% / 0.0%
FY2021-FY2025
Trend
+100.0%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Return on Equity (ROE) returned to growth in FY2025 after 2 years of decline, reaching 0.0%.
Based on SEC 10-K filings.
0.0% in FY2025 with a 5-year CAGR of +206.9%.
Improved from -30.2% to 0.0% over the past 2 years.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- +1.4pp
- 5-Year Change
- +206.9pp
- 10-Year Change
- -
Key checks
Key Insights
- In FY2025, return on equity (roe) increased 100.0% year-over-year.
- Peak return on equity (roe) was recorded in FY2013.
- Lowest return on equity (roe) in the period was in FY2020.
Company context
Key Data Points
- Altman Z-Score -1.16 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | 0.0% | +100.0% |
| FY2024 | -80.3% | -165.9% |
| FY2023 | -30.2% | -2071.9% |
| FY2022 | -1.4% | +99.0% |
| FY2021 | -136.7% | +33.9% |
| FY2020 | -206.9% | -67.4% |
| FY2019 | -123.6% | -23.6% |
| FY2018 | -100.0% | -236.7% |
| FY2013 | 73.1% | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026